Tryptamine Therapeutics Ltd (TYP)

Sydney
Currency in AUD
0.036
0.000(0.00%)
Delayed Data·
TYP Scorecard
Full Analysis
Analysts anticipate sales growth in the current year
TYP is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.0360.036
52 wk Range
0.0170.057
Key Statistics
Edit
Bid/Ask
0.036 / 0.037
Prev. Close
0.036
Open
0.036
Day's Range
0.036-0.036
52 wk Range
0.017-0.057
Volume
112.12K
Average Volume (3m)
1.75M
1-Year Change
227.27%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
TYP Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins
Show more

Tryptamine Therapeutics Ltd Company Profile

Tryptamine Therapeutics Limited, a clinical-stage pharmaceutical development company, focuses on developing synthetic psilocybin-related molecules in Australia, Canada, Switzerland, and the United States. The company’s lead program candidate TRP-8803, a proprietary formulation of IV-infused psilocin that completed Phase 2 clinical trial for the treatment of binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. It is also involved in the development of TRP-8802, a synthetic and oral psilocybin, currently under phase 2a clinical stager for the treatment of binge eating, as well as under phase 2 clinical stage for the treatment of fibromyalgia, and irritable bowel syndrome. The company was founded in 2019 and is based in Camberwell, Australia.

Compare TYP to Peers and Sector

Metrics to compare
TYP
Peers
Sector
Relationship
P/E Ratio
−7.0x−5.5x−0.5x
PEG Ratio
−0.52−0.020.00
Price/Book
-4.4x2.6x
Price / LTM Sales
39.0x12.6x3.0x
Upside (Analyst Target)
-275.0%54.1%
Fair Value Upside
Unlock2.7%8.7%Unlock

Earnings

Latest Release
Apr 30, 2025
EPS / Forecast
-- / -0.01
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

FAQ

What Is the Tryptamine Therapeutics (TYP) Stock Price Today?

The Tryptamine Therapeutics stock price today is 0.04

What Stock Exchange Does Tryptamine Therapeutics Trade On?

Tryptamine Therapeutics is listed and trades on the Sydney Stock Exchange stock exchange.

What Is the Stock Symbol for Tryptamine Therapeutics?

The stock symbol for Tryptamine Therapeutics is "TYP."

What Is the Tryptamine Therapeutics Market Cap?

As of today, Tryptamine Therapeutics market cap is 51.80M.

What Is Tryptamine Therapeutics's Earnings Per Share (TTM)?

The Tryptamine Therapeutics EPS (TTM) is -0.01.

When Is the Next Tryptamine Therapeutics Earnings Date?

Tryptamine Therapeutics will release its next earnings report on 29 July 2025.

From a Technical Analysis Perspective, Is TYP a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.